Intramyocardial Haemorrhage in Patients With Primary STEMI (HaemInCor)
Myocardial Infarction, STEMI, Myocardial Necrosis
About this trial
This is an interventional diagnostic trial for Myocardial Infarction focused on measuring Intramyocardial haemorrhage, Myocardial Infarction, ST Elevation Myocardial Infarction, Primary Percutaneous Coronary Intervention, Pharmaco invasive strategy, Fibrinolytic therapy, Global longitudinal strain, Myocardial Necrosis, Coronary Artery Disease
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years at time of randomization (18 years and older);
- Acute myocardial infarction;
- Reperfusion of the infarct-related coronary artery in terms within 12 h of symptom onset;
- Written the informed consent to participate in research;
Exclusion Criteria:
- Inability to obtain informed consent;
- Patients previously undergone endovascular / surgical revascularization of coronary artery;
- Severe comorbidity;
- History of myocardial infarction;
- History of intracranial haemorrhage;
- Pulmonary edema, cardiogenic shock;
- Creatinine clearance <30 mL/min or dialysis;
- Unable to undergo or contra-indications for MRI;
- Allergy for contrast agent;
- Indication or use of oral anticoagulant therapy;
- Major bleedind;
- Atrio-ventricular block II and III degree;
- Active gastroduodenal ulcer;
- Aortic dissection;
- Acute psychotic disorders
Sites / Locations
- Cardiology Research Institute
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Pharmaco-invasive strategy
Primary PCI
Fibrinolytic therapy (Streptokinase, Alteplasa, Tenecteplasa in standard dose) is conducted within 12 h of symptom onset in the pre-hospital setting if primary PCI cannot be performed within 120 min from STEMI diagnosis. Then PCI is performed to all of patients.
Primary percutaneous coronary intervention (PCI) in patients with primary STEMI